ASR Vermogensbeheer’s BioMarin Pharmaceuticals BMRN Stock Holding History

ASR Vermogensbeheer’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,361	Closed	-$236K	–	536
2025 Q3	$236K	Sell	4,361 -50	-1%	-$2.86K	﹤0.01%	538
2025 Q2	$242K	Sell	4,411 -23	-0.5%	-$1.35K	﹤0.01%	543
2025 Q1	$313K	Buy	+4,434	New	+$298K	﹤0.01%	534

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ASR Vermogensbeheer's BMRN Position: Q4 2025 in Review

ASR Vermogensbeheer sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,361 shares — an estimated $236K sold.

ASR Vermogensbeheer first reported a position in BMRN in Q1 2025 and held it in 3 quarters. The position peaked at $313K in Q1 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

ASR Vermogensbeheer reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
ASR Vermogensbeheer sold 4,361 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $236K.
ASR Vermogensbeheer first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 3 quarters.
ASR Vermogensbeheer's BioMarin Pharmaceuticals position peaked at $313K in Q1 2025.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on ASR Vermogensbeheer's 13F filing for Q4 2025, filed 3 Feb 2026.